Lenvatinib

Generic Name: Lenvatinib

Brand Names: Lenvima 10, Kisplyx, Lenvima

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉ClN_₄O_₄

CAS Number: 417716-92-8

Unique Ingredient Identifier: EE083865G2

Background: Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication: Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions: Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)

Associated Therapies: -

Clinical Trials

Neoantigen Derived DCs as Cancer Treatment

Phase 1

Recruiting

Conditions: Solid Tumor
Refractory Tumor

Interventions: Biological: Dendritic Cell Vaccine
Drug: Lenvatinib
Drug: Nivolumab

First Posted Date: 2023-03-14

Last Posted Date: 2023-08-25

Lead Sponsor: National Health Research Institutes, Taiwan

Target Recruit Count: 12

Registration Number: NCT05767684

Locations: 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
🇨🇳
National Institute of Cancer Research, Tainan, Taiwan

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2

Recruiting

Conditions: Well-Differentiated Neuroendocrine Carcinoma
High Grade Neuroendocrine Carcinoma, Any Site
Neuroendocrine Tumors

Interventions: Drug: Lenvatinib
Drug: Pembrolizumab
Drug: Hyperpolarized 13C-Pyruvate

First Posted Date: 2023-02-27

Last Posted Date: 2024-12-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 29

Registration Number: NCT05746208

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: F520
Drug: Lenvatinib

First Posted Date: 2023-02-22

Last Posted Date: 2023-02-22

Lead Sponsor: Shandong New Time Pharmaceutical Co., LTD

Target Recruit Count: 158

Registration Number: NCT05740215

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China

SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)

Phase 3

Not yet recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib
Procedure: TACE
Radiation: SBRT

First Posted Date: 2023-02-08

Last Posted Date: 2023-02-08

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 136

Registration Number: NCT05718232

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting

Conditions: Hepatocellular Carcinoma Non-resectable

Interventions: Procedure: TACE
Drug: Bevacizumab plus Atezolizumab
Drug: apatinib plus camrelizumab
Drug: Bevacizumab Biosimilar IBI305 plus sintilimab
Drug: Lenvatinib
Drug: Anti-PD-1 monoclonal antibody
Drug: Donafenib
Drug: Sorafenib
Drug: Regorafenib

First Posted Date: 2023-02-08

Last Posted Date: 2024-06-13

Lead Sponsor: Tongji Hospital

Target Recruit Count: 300

Registration Number: NCT05717738

Locations: 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 1 locations

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

Conditions: Hepatocellular Carcinoma Non-resectable

Interventions: Procedure: HAIC
Drug: apatinib plus camrelizumab
Drug: Bevacizumab Biosimilar IBI305 plus sintilimab
Drug: Donafenib
Drug: Bevacizumab plus Atezolizumab
Drug: Sorafenib
Drug: Lenvatinib
Drug: Regorafenib
Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2023-02-06

Last Posted Date: 2023-12-22

Lead Sponsor: Wan-Guang Zhang

Target Recruit Count: 300

Registration Number: NCT05713994

Locations: 🇨🇳
TongjiHospital, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Phase 2

Active, not recruiting

Conditions: Anaplastic Thyroid Cancer

Interventions: Drug: Lenvatinib
Drug: Nivolumab

First Posted Date: 2023-01-25

Last Posted Date: 2024-03-21

Lead Sponsor: National Cancer Center Hospital East

Target Recruit Count: 51

Registration Number: NCT05696548

Locations: 🇯🇵
Nippon Medical School Hospital, Tokyo, Japan
🇯🇵
Osaka Metropolitan University Hospital, Osaka, Japan
🇯🇵
Aichi Cancer Center, Nagoya, Aichi, Japan

and more 7 locations

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Oncorine
Drug: Tislelizumab
Drug: Lenvatinib

First Posted Date: 2023-01-09

Last Posted Date: 2023-03-06

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05675462

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Not Applicable

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: HAIC
Drug: Sintilimab
Drug: Lenvatinib

First Posted Date: 2022-11-18

Last Posted Date: 2022-11-18

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT05621499

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Phase 3

Recruiting

Conditions: Hepatocellular Carcinoma Non-resectable

Interventions: Procedure: Lenvatinib Plus I-125 Seed Brachytherapy
Drug: Lenvatinib

First Posted Date: 2022-11-08

Last Posted Date: 2022-11-08

Lead Sponsor: Second Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 187

Registration Number: NCT05608213

Locations: 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy